Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rangering i aksjer #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Aksjekurs
$150.78
Sist synkronisert: 2026-09-18
Markedsverdi
$187.20B
Endring (1 dag)
-0.08%
Endring (1 år)
32.15%
Land
US
Handel Gilead Sciences, Inc. (GILD)

Kategori

P/B-forhold for Gilead Sciences, Inc. (GILD)
P/B-forhold per September 2026 TTM: 15.39
Ifølge Gilead Sciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 15.39. Ved slutten av 2024 hadde selskapet et P/B-forhold på 5.96.
P/B-historikk for Gilead Sciences, Inc. fra 2000 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 15.39 -100.00%
2025 0.00 -100.00%
2024 5.96 34.58%
2023 4.43 -12.71%
2022 5.07 17.19%
2021 4.33 7.59%
2020 4.02 9.82%
2019 3.66 -3.49%
2018 3.80 -17.12%
2017 4.58 -9.78%
2016 5.08 -36.48%
2015 7.99 -14.05%
2014 9.30 -7.89%
2013 10.10 68.83%
2012 5.98 27.09%
2011 4.71 -11.06%
2010 5.29 -13.96%
2009 6.15 -44.20%
2008 11.02 -10.79%
2007 12.35 -24.75%
2006 16.42 108.13%
2005 7.89 -2.41%
2004 8.08 -30.89%
2003 11.69 0.49%
2002 11.64 -15.83%
2001 13.83 28.66%
2000 10.75 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
29.9692 94.78%
US
7.6479 -50.29%
US
-78.0908 -607.54%
US
8.4776 -44.90%
CH
8.5385 -44.51%
US